Using Cancer Data to Improve Performance and Reduce Delays

Why It Matters

Without actionable, real‑time data Scotland cannot meet its cancer targets, risking poorer outcomes and widening health inequities. Leveraging data-driven pathways directly improves patient survival and system efficiency.

Key Takeaways

• 69.9% meet 62‑day target, far below 95% goal
• Denmark cut delays using real‑time cancer dashboards
• Glasgow reduced longest waits 42% in 100 days
• Real‑time data links capacity, staffing, diagnostics
• Inequalities rise 24% in deprived Scottish communities

Pulse Analysis

Scotland’s cancer care faces a critical bottleneck: diagnostic and treatment delays that jeopardise patient outcomes. While the 2025 National Framework sets a clear roadmap, progress stalls without a unified data foundation. Real‑time analytics enable health boards to pinpoint where referrals stall—whether in imaging, pathology, or specialist review—and to reallocate staff and equipment swiftly. This granular visibility transforms reactive management into proactive, data‑driven decision‑making, aligning resources with demand and reducing wasted capacity.

International benchmarks illustrate the power of data. Denmark’s national cancer programme, built on comprehensive, stage‑at‑diagnosis reporting and live dashboards, has slashed waiting times and narrowed regional disparities. Their approach demonstrates that consistent definitions and interoperable datasets can turn raw information into actionable insight, guiding everything from early‑detection campaigns to clinical‑trial recruitment. Scotland’s own Glasgow health board proved the concept locally, cutting its longest cancer waits by 42% within 100 days by harnessing complete, accurate data to eliminate bottlenecks.

For Scotland to replicate and scale these gains, a single, national data layer is essential. By aggregating referral, diagnostic, staging, and treatment metrics across all boards, policymakers can monitor capacity, track health‑inequality indicators, and trigger timely interventions. Such a system would empower clinicians with the same view, fostering collaboration across geographic boundaries and ensuring that every pound spent yields maximum patient benefit. In an era where health outcomes increasingly hinge on information flow, investing in real‑time cancer data is not optional—it is the linchpin for meeting targets, improving survival rates, and delivering equitable care.